Education
About Us
Working with TipRanks
Follow Us
Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ:VNDA
Earnings Data
Report Date
May 06, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.69Last Year’s EPS
-0.5Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a balanced mix of strong commercial momentum and regulatory progress alongside material near-term financial and execution challenges. Highlights include robust Fanapt prescription growth, a meaningful FY revenue increase, FDA approval of Nereus and multiple late-stage pipeline advances with revenue guidance implying continued growth. Lowlights include a large FY net loss driven in part by a one-time $113.7M valuation allowance, substantially higher operating expenses, declining HETLIOZ sales amid generic competition, reduced cash balances with expected higher cash burn in 2026, and some clinical enrollment and inventory timing risks. Given the sizable commercial and regulatory positives tempered by significant near-term financial and execution risks, the overall tone is cautiously balanced.Company Guidance
Fanapt Strong Commercial Growth
Full-year Fanapt net product sales rose 24% to $117.3M (2025 vs 2024); total prescriptions (TRx) increased 28% and new-to-brand prescriptions (NBRx) surged 149% for the year. Q4 Fanapt sales were $33.2M, up 25% YoY and 6% QoQ; Q4 TRx +36% YoY and NBRx +108% YoY.
Company Revenue Growth
Total revenues for FY2025 were $216.1M, a 9% increase vs $198.8M in FY2024; Q4 revenues were $57.2M, up 8% YoY and 2% QoQ.
Regulatory Approval for Nereus (tradipitant)
FDA approved tradipitant (Nereus) on December 30, 2025 for prevention of motion-induced vomiting — described as the first new oral pharmacologic option in the space in over 40 years; commercial availability expected late Q2 / early Q3 2026.
Robust Late-Stage Pipeline and Recent Submissions
Imsidolimab BLA submitted in Q4 2025 for generalized pustular psoriasis with regulatory/patent exclusivity expected into the late 2030s; an NDA under FDA review for bipolar 1 disorder/schizophrenia with PDUFA Feb 21, 2026; multiple Phase III programs ongoing (MDD adjunct, iloperidone LAI for relapse prevention, VQW765 for SAD, PONVORY trials in psoriasis and UC).
Guidance and Growth Outlook
2026 revenue guidance for marketed products of $230M–$260M (midpoint implies ≈13% growth vs 2025); Fanapt guidance $150M–$170M (midpoint implies ≈36% growth vs 2025) with management attributing growth primarily to TRx/volume expansion.
Commercial Capability Expansion
Sales force expanded from ~160 reps at end of 2024 to ~300 reps at end of 2025 (plus ~50 specialty reps); face-to-face calls more than doubled YoY and a direct-to-consumer campaign launched in Q1 2025 to boost brand awareness.
PONVORY Sequential Improvement
PONVORY net product sales stable to slightly down for year ($27.4M, -2% YoY) but Q4 showed improvement to $7.6M (+17% YoY, +8% QoQ) with underlying patient demand modestly increasing sequentially over the last three quarters.
VNDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VNDA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 11, 2026 | $7.43 | $6.12 | -17.63% |
Oct 29, 2025 | $5.41 | $4.32 | -20.15% |
Jul 31, 2025 | $4.67 | $4.26 | -8.78% |
May 07, 2025 | $4.38 | $4.22 | -3.65% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Vanda Pharmaceuticals Inc. (VNDA) report earnings?
Vanda Pharmaceuticals Inc. (VNDA) is schdueled to report earning on May 06, 2026, After Close (Confirmed).
What is Vanda Pharmaceuticals Inc. (VNDA) earnings time?
Vanda Pharmaceuticals Inc. (VNDA) earnings time is at May 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VNDA EPS forecast?
VNDA EPS forecast for the fiscal quarter 2026 (Q1) is -0.69.